131 related articles for article (PubMed ID: 22687971)
21. Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes.
Rosso V; Petiti J; Dragani M; Andreani G; Croce E; Lo Iacono M; Saglio G; Fava C; Cilloni D
Ann Hematol; 2020 Apr; 99(4):891-893. PubMed ID: 32016578
[No Abstract] [Full Text] [Related]
22. Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome.
Lin J; Qian J; Yao DM; Qian W; Yang J; Wang CZ; Chai HY; Ma JC; Deng ZQ; Li Y; Chen Q
Leuk Res; 2013 Jan; 37(1):71-5. PubMed ID: 23122807
[TBL] [Abstract][Full Text] [Related]
23. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
[TBL] [Abstract][Full Text] [Related]
24.
Komrokji R; Al Ali N; Chan O; Sweet K; Kuykendall A; Lancet J; Padron E; Sallman DA
Haematologica; 2023 Apr; 108(4):1168-1172. PubMed ID: 36420802
[No Abstract] [Full Text] [Related]
25. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
26. Histiocytoid Sweet syndrome harboring an isocitrate dehydrogenase 1 mutation: A case report and retrospective analysis of 29 cases of histiocytoid Sweet syndrome.
Libby TJ; Fleming K; Amin B
J Cutan Pathol; 2019 Apr; 46(4):290-292. PubMed ID: 30632174
[TBL] [Abstract][Full Text] [Related]
27. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
[TBL] [Abstract][Full Text] [Related]
28. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).
Pardanani A; Patnaik MM; Lasho TL; Mai M; Knudson RA; Finke C; Ketterling RP; McClure RF; Tefferi A
Leukemia; 2010 Jul; 24(7):1370-2. PubMed ID: 20485375
[No Abstract] [Full Text] [Related]
29. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
Zhu C; Ma Y; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
[TBL] [Abstract][Full Text] [Related]
30. Effects of azacitidine in 93 patients with
Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
[TBL] [Abstract][Full Text] [Related]
31. Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.
Tischer A; Antelo G; Coltro G; Finke CM; Gonsalves W; Pardanani A; Ketterling R; Mangaonkar A; Gangat N; Tefferi A; Patnaik MM; Lasho TL
Leuk Res; 2019 Dec; 87():106264. PubMed ID: 31706195
[No Abstract] [Full Text] [Related]
32. Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Zhang Y; Wei H; Tang K; Lin D; Zhang C; Mi Y; Wang L; Wang C; Wang M; Wang J
Genet Test Mol Biomarkers; 2012 Aug; 16(8):991-5. PubMed ID: 22809434
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
34. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
36. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
[TBL] [Abstract][Full Text] [Related]
37. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
38. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
39. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]